TBAJ-587, a novel diarylquinoline, is active against Mycobacterium abscessus
Antimicrobial Agents and Chemotherapy · 05.12.2024 · 68 (12)
DOI: 10.1128/aac.00945-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 05.12.2024. Verfasst von Junsheng Fan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China. Hauptthemen laut MEDLINE: Mycobacterium abscessus, Diarylquinolines, Microbial Sensitivity Tests, Mycobacterium Infections, Nontuberculous. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MOST | National Natural Science Foundation of China (NSFC), STCSM | Natural Science Foundation of Shanghai Municipality (), STCSM | Science and Technology Innovation Plan Of Shanghai Science and Technology Commission ().
Abstract (Originalsprache)
Nontuberculous mycobacteria (NTM) infections are extremely difficult to treat due to a natural resistance to many antimicrobials. TBAJ-587 is a novel diarylquinoline, which shows higher anti-tuberculosis activity, lower lipophilicity, and weaker inhibition of hERG channels than bedaquiline (BDQ). The susceptibilities of 11 NTM reference strains and 194 clinical Mycobacterium abscessus isolates to TBAJ-587 were determined by the broth microdilution assay. The activity of TBAJ-587 toward the growth of M. abscessus in macrophages was also evaluated. Minimum bactericidal concentration and time-kill kinetic assays were conducted to distinguish between the bactericidal and bacteriostatic activities of TBAJ-587. The synergy between TBAJ-587 and eight clinically important antibiotics was determined using a checkerboard assay. TBAJ-587 was highly effective against M. abscessus by targeting its F-ATP synthase c chain. The antimicrobial activities of TBAJ-587 and BDQ toward intracellular M. abscessus were comparable. The in vivo activities of TBAJ-587 and BDQ in an immunocompromised mouse model were also comparable. TBAJ-587 expressed bactericidal activity and was compatible with eight anti-NTM drugs commonly used in clinical practice; no antagonism was discovered. As such, TBAJ-587 represents a potential candidate for the treatment of NTM infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory and Critical Care Medicine, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
- School of Medicine, Tongji University, Shanghai, China.
- Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
ORCID-Profile: Junsheng Fan, Bing Li, Haiqing Chu
Förderung
- MOST | National Natural Science Foundation of China (NSFC)
- STCSM | Natural Science Foundation of Shanghai Municipality ()
- STCSM | Science and Technology Innovation Plan Of Shanghai Science and Technology Commission ()
- Clinical Research foundation of Shanghai Pulmonary Hospital
Zitieren
APA
Fan, J., Tan, Z., He, S., Li, A., Jia, Y., Li, J., Zhang, Z., Li, B., & Chu, H. (2024). TBAJ-587, a novel diarylquinoline, is active against Mycobacterium abscessus. Antimicrobial Agents and Chemotherapy, 68(12). https://doi.org/10.1128/aac.00945-24
Vancouver
Fan J, Tan Z, He S, Li A, Jia Y, Li J, et al. TBAJ-587, a novel diarylquinoline, is active against Mycobacterium abscessus. Antimicrobial Agents and Chemotherapy. 2024;68(12). doi:10.1128/aac.00945-24
BibTeX
@article{Fan2024,
author = {Fan, Junsheng and Tan, Zhili and He, Siyuan and Li, Anqi and Jia, Yaping and Li, Juan and Zhang, Zhemin and Li, Bing and Chu, Haiqing},
title = {TBAJ-587, a novel diarylquinoline, is active against Mycobacterium abscessus},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2024},
volume = {68},
number = {12},
doi = {10.1128/aac.00945-24}
}
EUVIMED